Joseph Barker

Joseph Barker

Auto-generated profile, based on publicly available information

Joseph Barker

National Heart and Lung Institute, Imperial College London , Du Cane Road, London W12 0NN

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DKDavid Koeckerling
David Koeckerling
PRPeter Francis Raguindin
Peter Francis Raguindin
LKLum Kastrati
Lum Kastrati
SBSarah Bernhard
Sarah Bernhard
JBJoseph Barker
Joseph Barker
IBIris Baumgartner
Iris Baumgartner
Aims: Optimal endovascular management of intermittent claudication (IC) remains disputed. This systematic review and meta-analysis compares efficacy and safety outcomes for balloon angioplasty (BA), bare-metal stents (BMS), drug-coated balloons (DCB), drug-eluting stents (DES), covered stents, and atherectomy.Methods and results: Electronic databases were searched for randomized, controlled trials (RCT) from inception through November 2021. Efficacy outcomes were primary patency, target-lesion revascularization (TLR), and quality-of-life (QoL). Safety endpoints were all-cause mortality and major amputation. Outcomes were evaluated at short-term (<1 year), mid-term (1–2 years), and long-term (≥2 years) follow-up. The study was registered on PROSPERO (CRD42021292639). Fifty-one RCTs enrolling 8430 patients/lesions were included. In femoropopliteal disease of low-to-intermediate complexity, DCBs were associated with higher likelihood of primary patency [short-term: odds ratio (OR) 3.21, 95% confidence interval (CI) 2.44–4.24; long-term: OR 2.47, 95% CI 1.93–3.16], lower TLR (short-term: OR 0.33, 95% CI 0.22–0.49; long-term: OR 0.42, 95% CI 0.29–0.60) and similar all-cause mortality risk, compared with BA. Primary stenting using BMS was associated with improved short-to-mid-term patency and TLR, but similar long-term efficacy compared with provisional stenting. Mid-term patency (OR 1.64, 95% CI 0.89–3.03) and TLR (OR 0.50, 95% CI 0.22–1.11) estimates were comparable for DES vs. BMS. Atherectomy, used independently or adjunctively, was not associated with efficacy benefits compared with drug-coated and uncoated angioplasty, or stenting approaches. Paucity and heterogeneity of data precluded pooled analysis for aortoiliac disease and QoL endpoints.Conclusion: Certain devices may provide benefits in femoropopliteal disease, but comparative data in aortoiliac arteries is lacking. Gaps in evidence quantity and quality impede identification of the optimal endovascular approach to IC.

16 June 2020 in Thorax
Verified
Journal Article
Open access
PDF file
DKDavid Koeckerling
David Koeckerling
JBJoseph Barker
Joseph Barker
NMNadeesha L Mudalige
Nadeesha L Mudalige
OOOluwatobiloba Oyefeso
Oluwatobiloba Oyefeso
DPDaniel Pan
Daniel Pan
GNG. André Andre Ng
G. André Andre Ng

25 August 2022 in EP Europace
Verified
Journal Article
Closed access
PDF file
JBJoseph Barker
Joseph Barker
XLXin Li
Xin Li
SKSarah Khavandi
Sarah Khavandi
DKDavid Koeckerling
David Koeckerling
AMAkash Mavilakandy
Akash Mavilakandy
GNG. André Andre Ng
G. André Andre Ng
Most patients who receive implantable cardioverter defibrillators (ICDs) for primary prevention do not receive therapy during the lifespan of the ICD, whilst up to 50% of sudden cardiac death (SCD) occur in individuals who are considered low risk by conventional criteria. Machine learning offers a novel approach to risk stratification for ICD assignment. Systematic search was performed in MEDLINE, Embase, Emcare, CINAHL, Cochrane Library, OpenGrey, MedrXiv, arXiv, Scopus, and Web of Science. Studies modelling SCD risk prediction within days to years using machine learning were eligible for inclusion. Transparency and quality of reporting (TRIPOD) and risk of bias (PROBAST) were assessed. A total of 4356 studies were screened with 11 meeting the inclusion criteria with heterogeneous populations, methods, and outcome measures preventing meta-analysis. The study size ranged from 122 to 124 097 participants. Input data sources included demographic, clinical, electrocardiogram, electrophysiological, imaging, and genetic data ranging from 4 to 72 variables per model. The most common outcome metric reported was the area under the receiver operator characteristic (n = 7) ranging between 0.71 and 0.96. In six studies comparing machine learning models and regression, machine learning improved performance in five. No studies adhered to a reporting standard. Five of the papers were at high risk of bias. Machine learning for SCD prediction has been under-applied and incorrectly implemented but is ripe for future investigation. It may have some incremental utility in predicting SCD over traditional models. The development of reporting standards for machine learning is required to improve the quality of evidence reporting in the field.

9 April 2020 in Thorax
Verified
Journal Article
Open access
PDF file
JBJoseph Barker
Joseph Barker
OOOluwatobiloba Oyefeso
Oluwatobiloba Oyefeso
DKDavid Koeckerling
David Koeckerling
NMNadeesha Lakmal Mudalige
Nadeesha Lakmal Mudalige
DPDaniel Pan
Daniel Pan

19 February 2025 in Medicina
Verified
Journal Article
Open access
PDF file
IAIbrahim Antoun
Ibrahim Antoun
Georgia R. LaytonGeorgia R. Layton
Georgia R. Layton
ANAli Nizam
Ali Nizam
JBJoseph Barker
Joseph Barker
Ahmed AbdelrazikAhmed Abdelrazik
Ahmed Abdelrazik
GNG. André Andre Ng
G. André Andre Ng
Background and objectives: Atrial fibrillation (AF), the most prevalent sustained arrhythmia, poses a significant public health challenge due to its links with stroke, heart failure, and mortality. Hypertension, a primary modifiable cardiovascular risk factor, is a well-established risk factor for AF that facilitates structural and electrical changes in the atria, including dilation, fibrosis, and pressure overload. Material and Methods: we conducted a literature search regarding the shared mechanisms, risks and treatments of hypertension and atrial fibrillation. Results: The renin–angiotensin–aldosterone system plays a pivotal role in this remodelling and inflammation, increasing AF susceptibility. Uncontrolled hypertension complicates AF management, diminishing the effectiveness of mainstay treatments, including antiarrhythmic drugs, catheter ablation, and cardioversion. Effective blood pressure management, particularly with therapies targeting the renin–angiotensin–aldosterone system (RAAS), can lower the risk of new-onset AF and reduce the incidence of recurrent AF, enhancing the success of rhythm control strategies. These antihypertensive therapies mitigate myocardial hypertrophy and fibrosis and attenuate both atrial pressure strain and the inflammatory response, mitigating the substrates for AF. Conclusion: This review highlights the urgent need for integrated strategies that combine BP control, AF screening, and lifestyle modifications to minimise the burden of AF and its complications. Future research should investigate the specific mechanisms of cellular-level interactions associated with a hypertensive predisposition to AF, including systematic inflammation and the role of genetics, the impact of blood pressure variations on AF risk, and individualised treatment strategies specifically targeting the shared mechanisms, simultaneously propagating hypertension and AF.

1 June 2020 in Resuscitation
Verified
Journal Article
Closed access
JBJoseph Barker
Joseph Barker
DKDavid Koeckerling
David Koeckerling
RWRaha West
Raha West